86 related articles for article (PubMed ID: 24032379)
1. Faster, higher, stronger.
Rubin BK
Am J Respir Crit Care Med; 2013 Sep; 188(6):634-5. PubMed ID: 24032379
[No Abstract] [Full Text] [Related]
2. Poly-L-Lysine compacts DNA, kills bacteria, and improves protease inhibition in cystic fibrosis sputum.
Dubois AV; Midoux P; Gras D; Si-Tahar M; Bréa D; Attucci S; Khelloufi MK; Ramphal R; Diot P; Gauthier F; Hervé V
Am J Respir Crit Care Med; 2013 Sep; 188(6):703-9. PubMed ID: 23947381
[TBL] [Abstract][Full Text] [Related]
3. Additive effect of dornase alfa and Nacystelyn on transportability and viscoelasticity of cystic fibrosis sputum.
Sun F; Tai S; Lim T; Baumann U; King M
Can Respir J; 2002; 9(6):401-6. PubMed ID: 12522485
[TBL] [Abstract][Full Text] [Related]
4. Effect of recombinant human DNase on alpha1-proteinase inhibitor function: an experimental approach to the combined clinical use of rhDNase and alpha1-PI in CF patients.
Hansen G; Hoffjan S; Mosler K; Schuster A
Lung; 2001; 179(3):185-94. PubMed ID: 11891608
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and sputum penetration of azithromycin during once weekly dosing in cystic fibrosis patients.
Wilms EB; Touw DJ; Heijerman HG
J Cyst Fibros; 2008 Jan; 7(1):79-84. PubMed ID: 17599845
[TBL] [Abstract][Full Text] [Related]
6. The effect of erythromycin on mucociliary transportability and rheology of cystic fibrosis and bronchiectasis sputum.
Shibuya Y; Wills PJ; Cole PJ
Respiration; 2001; 68(6):615-9. PubMed ID: 11786718
[TBL] [Abstract][Full Text] [Related]
7. Dornase aerosol effect on sputum viscosity in cases of cystic fibrosis.
Lieberman J
JAMA; 1968 Jul; 205(5):312-3. PubMed ID: 5694947
[No Abstract] [Full Text] [Related]
8. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis.
Cunningham S; McColm JR; Mallinson A; Boyd I; Marshall TG
Pediatr Pulmonol; 2003 Jul; 36(1):43-8. PubMed ID: 12772222
[TBL] [Abstract][Full Text] [Related]
9. Effect of tolazoline hydrochloride on sputum viscosity in cystic fibrosis.
Feather EA; Russell G
Thorax; 1970 Nov; 25(6):732-6. PubMed ID: 5494682
[TBL] [Abstract][Full Text] [Related]
10. Proteolytic enzyme activity and the role of desoxyribose nucleic acid (DNA) in cystic fibrosis sputum.
LIEBERMAN J; KURNICK NB
Pediatrics; 1963 Jun; 31():1028-32. PubMed ID: 13930542
[No Abstract] [Full Text] [Related]
11. [Pharmaccokinetics of various antibiotics on mucoviscidosis with special reference to their concentration in sputum in relation to its chemical composition].
Bonomi U; Marcer V; Piacentini I; Bravi A; Battaglino G; Stizzoli R; Mastella G
Fracastoro; 1970; 63(3):579-609. PubMed ID: 5517030
[No Abstract] [Full Text] [Related]
12. Trace incorporation of heavy water reveals slow and heterogeneous pathogen growth rates in cystic fibrosis sputum.
Kopf SH; Sessions AL; Cowley ES; Reyes C; Van Sambeek L; Hu Y; Orphan VJ; Kato R; Newman DK
Proc Natl Acad Sci U S A; 2016 Jan; 113(2):E110-6. PubMed ID: 26715741
[TBL] [Abstract][Full Text] [Related]
13. Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections.
Hisert KB; Heltshe SL; Pope C; Jorth P; Wu X; Edwards RM; Radey M; Accurso FJ; Wolter DJ; Cooke G; Adam RJ; Carter S; Grogan B; Launspach JL; Donnelly SC; Gallagher CG; Bruce JE; Stoltz DA; Welsh MJ; Hoffman LR; McKone EF; Singh PK
Am J Respir Crit Care Med; 2017 Jun; 195(12):1617-1628. PubMed ID: 28222269
[TBL] [Abstract][Full Text] [Related]
14. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
[TBL] [Abstract][Full Text] [Related]
15. Cysteamine as a Future Intervention in Cystic Fibrosis Against Current and Emerging Pathogens: A Patient-based ex vivo Study Confirming its Antimicrobial and Mucoactive Potential in Sputum.
Devereux G; Fraser-Pitt D; Robertson J; Devlin E; Mercer D; O'Neil D
EBioMedicine; 2015 Oct; 2(10):1507-12. PubMed ID: 26629546
[TBL] [Abstract][Full Text] [Related]
16. Acetylcysteine in the oral mucolytic treatment of cystic fibrosis.
Stephan U; Böwing B; Goering U; Wiesemann HG; Reinhardt M; Hirche H; Brandt H
Eur J Respir Dis Suppl; 1980; 111():127-31. PubMed ID: 6938396
[No Abstract] [Full Text] [Related]
17. The effect of augmentin on sputum beta-lactamase activity in patients with cystic fibrosis.
Penketh AR; Hodson ME; Batten JC
Br J Clin Pract; 1984 May; 38(5):188-9. PubMed ID: 6610437
[No Abstract] [Full Text] [Related]
18. Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.
Stigliani M; Manniello MD; Zegarra-Moran O; Galietta L; Minicucci L; Casciaro R; Garofalo E; Incarnato L; Aquino RP; Del Gaudio P; Russo P
J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):337-45. PubMed ID: 26741302
[TBL] [Abstract][Full Text] [Related]
19. Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Sanders NN; Franckx H; De Boeck K; Haustraete J; De Smedt SC; Demeester J
Thorax; 2006 Nov; 61(11):962-8. PubMed ID: 17071834
[TBL] [Abstract][Full Text] [Related]
20. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
Moriarty TF; McElnay JC; Elborn JS; Tunney MM
Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
